Metastatic Uveal Melanoma Clinical Trials

42 clinical trials for Metastatic Uveal Melanoma across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tebentafusp-tebn With LDT in Metastatic UM — RECRUITING · PHASE1
• A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma — RECRUITING · PHASE1
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — RECRUITING · PHASE1
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma — RECRUITING · PHASE1
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma — RECRUITING · PHASE2
• Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma — RECRUITING · PHASE2
• Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma — RECRUITING · PHASE2
• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma — RECRUITING · PHASE2
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma — RECRUITING · PHASE1
• Adding IL-2 to Tebentafusp to Eradicate Cancer Progression — RECRUITING · PHASE1
• A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma — COMPLETED · PHASE2
• Vorinostat in Treating Patients With Metastatic Melanoma of the Eye — ACTIVE_NOT_RECRUITING · PHASE2
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) — COMPLETED · PHASE2
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas — ACTIVE_NOT_RECRUITING · PHASE1
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver — COMPLETED · PHASE2
• Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors — NOT_YET_RECRUITING · PHASE1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases — ACTIVE_NOT_RECRUITING · PHASE2
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma — COMPLETED · PHASE2
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
• A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma — NOT_YET_RECRUITING · PHASE3
• Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases — COMPLETED · PHASE1
• Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma — NOT_YET_RECRUITING · PHASE1
• Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) — COMPLETED · NA
• Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma — TERMINATED · PHASE2
• Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM) — OTHER · PHASE2
• A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients — OTHER · PHASE2
• Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma — COMPLETED · PHASE2
• FHD-286 in Subjects With Metastatic Uveal Melanoma — TERMINATED · PHASE1
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma — OTHER · PHASE1
• An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye — COMPLETED · PHASE2
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma — TERMINATED · PHASE2
• Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma — WITHDRAWN · PHASE1
• A Study to Assess PV-10 Chemoablation of Cancer of the Liver — OTHER · PHASE1
• Clinical and Histopathologic Characteristics of BAP1 Mutations — COMPLETED
• A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma — COMPLETED · PHASE2
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma — TERMINATED · PHASE2
• Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma — WITHDRAWN · PHASE2

Refine this search